MAPT and Alzheimer disease: Specifically, the FDA-approved method developed by Avid Radiopharmaceuticals involves identifying whether there is contiguous radiotracer uptake greater than 1.65 times the cerebellar uptake in the posterolateral temporal, occipital, or parietal/precuneus regions to define AD or negative tau patterns [6].